NFKB1 and hematologic disorder: Therefore, targeting aberrant NF-κB activation together with its upstream and downstream interacting regulatory molecules using low molecular weight inhibitors, may be useful in clinical settings for the treatment of solid cancers and hematological malignancies [18].